Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROSiA: Bevacizumab with Carboplatin and Paclitaxel in Front-line Ovarian Cancer
NCT01239732Phase 3Completed
- Sponsor
- Roche
- Start
- Dec 2010
- Primary completion
- Mar 2015
- Modality
- Monoclonal Antibodies
- Countries
- 37
01
Overview
Phase 3, open-label, single-arm trial of bevacizumab in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Roche. Primary endpoint: Percentage of Participants With at Least One Adverse Event. Started Dec 2010; status: completed.
02
Drugs
bevacizumab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT01239732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01239732.